Emergent BioSolutions Files 8-K on Material Agreement
Ticker: EBS · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $56 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, corporate-event
Related Tickers: EBS
TL;DR
Emergent BioSolutions (EBS) filed an 8-K on Sep 5th for a material definitive agreement. Details to follow.
AI Summary
Emergent BioSolutions Inc. filed an 8-K on September 11, 2025, reporting on events that occurred on September 5, 2025. The filing indicates the entry into a material definitive agreement, a Regulation FD disclosure, and the filing of financial statements and exhibits. Specific details of the agreement and financial information were not provided in the excerpt.
Why It Matters
This filing signals a significant corporate event for Emergent BioSolutions, potentially impacting its business operations, financial standing, and investor relations.
Risk Assessment
Risk Level: medium — The filing of a material definitive agreement suggests a significant event that could carry financial or operational risks and rewards, requiring further investigation.
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- September 5, 2025 (date) — Earliest event reported
- September 11, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 14-1902018 (identifier) — Commission File Number
- 141902018 (identifier) — IRS Employer Identification No.
- 300 Professional Drive, Gaithersburg, Maryland 20879 (address) — Principal executive offices
- 240-631-3200 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Emergent BioSolutions?
The excerpt does not specify the nature of the material definitive agreement, only that one was entered into on September 5, 2025.
When was this Form 8-K filed with the SEC?
The Form 8-K was filed on September 11, 2025.
What is Emergent BioSolutions Inc.'s state of incorporation?
Emergent BioSolutions Inc. is incorporated in Delaware.
What is the address of Emergent BioSolutions' principal executive offices?
The principal executive offices are located at 300 Professional Drive, Gaithersburg, Maryland 20879.
What are the key items reported in this 8-K filing?
The key items reported are the entry into a material definitive agreement, a Regulation FD disclosure, and the filing of financial statements and exhibits.
Filing Stats: 693 words · 3 min read · ~2 pages · Grade level 10.1 · Accepted 2025-09-11 16:07:36
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
- $56 million — act"). Modification No. 14 is valued at $56 million and requires Emergent to deliver doses
Filing Documents
- ebs-20250905.htm (8-K) — 29KB
- a09092025acam2000pressrele.htm (EX-99.1) — 18KB
- image2.jpg (GRAPHIC) — 7KB
- 0001367644-25-000188.txt ( ) — 208KB
- ebs-20250905.xsd (EX-101.SCH) — 2KB
- ebs-20250905_def.xml (EX-101.DEF) — 15KB
- ebs-20250905_lab.xml (EX-101.LAB) — 26KB
- ebs-20250905_pre.xml (EX-101.PRE) — 16KB
- ebs-20250905_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement On September 5, 2025, Emergent BioSolutions Inc. (the "Company," including its wholly-owned subsidiaries, "Emergent"), through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response ("ASPR"), an agency of the U.S. Department of Health and Human Services ("Modification No. 14"), exercising Option Year 6 for Emergent to supply ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) to the U.S. government under Emergent's existing 10-year contract with ASPR (the "ACAM2000 Contract"). Modification No. 14 is valued at $56 million and requires Emergent to deliver doses of ACAM2000 to the U.S. government by December 31, 2025. The preceding description of Modification 14 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification 14. A copy of Modification 14 is expected to be filed as an exhibit to the Company's next Quarterly Report on Form 10-Q. The ACAM2000 Contract is filed as a material agreement of Emergent as exhibit 10.48 with the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 9, 2025, the Company issued a press release announcing Modification No. 14. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions Inc. on September 9, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: September 11, 2025 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer